Tianjin Pharmaceutical Group International Holdings

What Tianjin Pharmaceutical Group International Holdings does

Tianjin Pharmaceutical Group International Holdings (天津医药集团) is a Tianjin municipal state-owned pharmaceutical conglomerate operating one of China's most complete pharmaceutical industry chains. The group's business spans six strategic segments: green TCM (centered on listed subsidiary 津药达仁堂 600329.SH, covering herb cultivation, R&D, manufacturing, and commercial distribution), chemical drugs and biopharmaceuticals (led by 津药药业 600488.SH with API and formulation integration across 70+ steroid hormone and amino acid products), medical devices (ophthalmic diagnostic equipment via 津药迈达, listed on NEEQ), pharmaceutical distribution (津药太平 commercial platform), consumer health (郁美净 children's skincare with 47-year heritage, 4.525 billion bags cumulative sales), and asset/financial services. The group controls 119 wholly/partially-owned subsidiaries and 162 investee companies, with 1,300+ product varieties, 122 exclusive products, 599 drug approval numbers, and 1,400+ patents.

Core technology capabilities include China's pioneering 滴丸 (pill-dropping) formulation platform (速效救心丸 launched 1982, China's first modern TCM 滴丸), a digitized TCM whole-chain traceability system covering 60+ GAP-standard herb cultivation bases (selected as a national 'Digital Three Products' typical case), and an AI-embedded operational platform ('津药慧脑' integrated with DeepSeek) deployed across R&D, production, and marketing. Heritage brand portfolio includes 达仁堂 (founded 1914), 乐仁堂, 隆顺榕 (founded 1833), 京万红, and 郁美净, with five national-level intangible cultural heritage items including national secret-level formulations 速效救心丸 and 京万红软膏.

Revenue is generated through multiple streams: branded drug sales via hospital direct sales, OTC retail channels (chain pharmacies, 2,000 planned 达仁堂 brand stores), e-commerce and instant retail (Meituan, JD, Douyin partnerships), API exports to 20+ countries with US FDA cGMP, EU CEP, Australia TGA, and Brazil ANVISA certifications, pharmaceutical commercial distribution, and consumer health products. The group's parent is Shanghai Industrial Group (上实集团), with mixed state-strategic ownership structure under Tianjin SASAC. Most recent revenue disclosure for subsidiary 津药达仁堂 shows RMB 57.93 billion operating revenue for Q1-Q3 2023, with Suxiao Jiuxin Wan generating RMB 2+ billion in annual sales and multiple other exclusive products exceeding RMB 300 million.

Name

Tianjin Pharmaceutical Group International Holdings

Legal name

天津市医药集团有限公司

Website

https://pharm.cn

Company type

Private

Operating status

Operating

Short description

Tianjin Pharmaceutical Group International Holdings is a Tianjin municipal state-owned pharmaceutical conglomerate operating a full pharmaceutical value chain across TCM (led by 达仁堂), chemical APIs (津药药业), medical devices, distribution, and consumer health (郁美净), serving domestic and international markets with 1,300+ products.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

All Other Chemical Product and Preparation Manufacturing (32599)

akta.pro primary industry

Generic ANDA/Regulatory Affairs & Submissions (HLAIABAJ)

Keywords

• Pharmaceutical manufacturing
• Drug distribution
• Healthcare products
• Medical devices
• Active pharmaceutical ingredients

Headquarters

HQ city

Tianjin

HQ country

China

HQ region

Asia

Offices6 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Revenue model

1. 药品制造与销售: 集团核心收入来源，涵盖中药、化学药、生物药及大健康产品的研发、生产与销售。拥有599个药品批准文号、122个独家品种，制剂产品通过医院、药店及线上渠道触达终端患者。
2. 原料药出口: 津药药业作为全球知名甾体激素类药物和氨基酸原料药生产企业，向全球市场出口原料药产品，已通过欧盟CEP、澳大利亚TGA、美国FDA认证，并获得多个国家的GMP认证。
3. 品牌OTC及健康消费品: 以达仁堂、郁美净等老字号品牌，通过零售药店、电商平台、品牌专卖店等渠道销售OTC药品和化妆品护肤产品，如速效救心丸、京万红软膏、郁美净儿童霜等。
4. 医药商业流通: 以津药太平医药有限公司为龙头，打造'品种+网络+渠道'模式，应用国际先进的仓储管理系统和现代信息技术打造高效率的药品流通平台。
5. 集团财务服务: 天津医药集团财务有限公司为成员单位提供存款、贷款、票据贴现、资金结算、委托贷款、债券承销、财务顾问、信用鉴证及咨询代理、同业拆借、票据承兑、有价证券投资等金融服务。

Go-to-market motion3 records

Distribution channels8 records

Marketing channels9 records

Core offering

No source-attributed factual content describing Tianjin Pharmaceutical Group International Holdings' core offerings was provided in the input.

Product overview

Tianjin Pharmaceutical Group International Holdings (天津医药集团) operates a multi-segment pharmaceutical and consumer health portfolio across six strategic business areas: (1) 绿色中药板块 centered on 津药达仁堂集团 (SH600329) covering the full TCM value chain from herb cultivation to drug manufacturing; (2) 化药及生物药板块 led by 津药药业股份有限公司 (SH600488) with integrated API and formulation capabilities in steroids and amino acids; (3) 医疗器械板块 anchored by 天津迈达医学科技 and 天津中新科炬生物制药 (new三板 companies) for ophthalmic devices and diagnostics; (4) 商业板块 through 津药太平医药 for pharmaceutical distribution; (5) 消费者健康板块 with 天津郁美净集团 (children's skincare) and 津药普光 (medical materials); and (6) 资产及金融服务板块. The group holds 1,300+ product varieties across 119 wholly/partially-owned and 162 investee companies. Key TCM brands include 达仁堂制药厂, 乐仁堂, 隆顺榕, 第六中药厂, and 京万红药业 — collectively representing five National Intangible Cultural Heritage items and 122 exclusive products. The portfolio spans cardiovascular drugs (速效救心丸, 通脉养心丸), dermatology (京万红软膏), anti-infectives, oncology (紫龙金片), diabetes care (金芪降糖片), and consumer health (郁美净 children's skincare). APIs include 70+ steroid hormone and amino acid products exported globally. The group has also developed a proprietary digital TCM whole-chain traceability platform and AI-enabled intelligent office tools.

Differentiator

Problem solved

Functional benefit

Brands

• 达仁堂: 中华老字号，绿色中药板块核心品牌，主营心脑血管中成药，拥有速效救心丸等独家品种
• 乐仁堂
• 隆顺榕
• 京万红
• 郁美净
• 津药药业
• 第六中药厂
• 津药太平
• 迈达科技
• 津药迈达

Quantifiable outcome

• 速效救心丸累计销量突破1200亿粒，年销售额突破20亿元，锚定20亿元新目标
• +7 more outcomes

Named customers10 records

Segments8 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

Partnerships

Twelve partnerships are on record, tiered core and minor.

• Feishu (飞书)coreTechnology or Integration · 17 June 2026天津医药集团与飞书合作启动会暨签约仪式在津药大厦举行，标志着天津医药集团进入以AI为引擎、全面推动组织变革、深化数智化转型的新阶段。合作将分三阶段：5月底至6月底完成全员上线实现'用上飞书'；7月聚焦专项落地推动'用好飞书'；8月起深化价值应用实现'用深飞书'，培养至少200位业务骨干，打造30个以上标杆案例。
• Jointown Pharmaceutical Group (九州通医药集团)coreChannel Partner/ Reseller/ Distributor · 13 January 2026集团旗下津药药业健康科技公司与九州通医药集团签订战略合作协议，共同打造更具韧性与竞争力的业务合作体系，围绕'品种聚焦、渠道下沉、服务升级'的合作方向，在品牌推广、市场秩序规范、终端网络覆盖等核心领域深化协作。九州通具有全国性分销网络、高效供应链服务和终端渠道覆盖优势。
• Huawei (华为)coreTechnology or Integration · 16 May 2025津药达仁堂-华为全面深化合作启动会召开，双方自2023年起展开合作，2025年联合申报的'人工智能+中医药多场景数字化应用建设'项目成为天津市制造业高质量发展专项中人工智能领域医药企业唯一入选项目。双方计划在数字化转型、云基础设施建设、生态联盟构建等多个维度深化合作。
• Tianjin University of Traditional Chinese Medicine (天津中医药大学)coreStrategic or Co-development Partner达仁堂与天津中医药大学深度合作，共建现代海河实验室、院士创新联合体等产学研平台，围绕速效救心丸、清咽滴丸等核心品种开展循证研究与二次开发。张伯礼院士担任学术带头人，推动中药现代化三十年研究成果发布及临床疗效评价。
• University of Macau (澳门大学)coreStrategic or Co-development Partner津药达仁堂与澳门大学共建中华医药创新联合实验室，聚焦面向国际市场创新中药研发，开展中药现代化关键技术的联合攻关。
• Nankai University Business School (南开大学商学院)minorStrategic or Co-development Partner南开大学商学院40余名师生走进津药郁美净，双方共同为'南开大学·津药郁美净就业实践基地'举行授牌仪式，围绕老字号品牌焕新、产教融合模式、复合型人才培养等话题展开深入探讨。
• China Cardiovascular Health Alliance (中国心血管健康联盟)coreStrategic or Co-development Partner达仁堂与中国心血管健康联盟合作推进胸痛救治单元推广工作，将中医药融入心血管疾病防治体系，速效救心丸纳入胸痛救治体系，建立6000+公益救助站，培训20000+名急救骨干。
• Meituan Healthcare (美团医药)minorGTM or Marketing Partner达仁堂与美团医药在即时零售领域开展深度合作，2025年即时零售GTV同比增长41%，商品曝光量达1.3亿次，速效救心丸稳居心脑血管类目第一，京万红软膏增速位列烫伤烧伤类目第三。
• Haihe Laboratory of Modern Chinese Medicine (现代海河实验室)coreStrategic or Co-development Partner达仁堂依托现代海河实验室和院士创新联合体，在全球布局产学研合作平台，以产业需求牵引科研方向，以科技创新反哺产业升级。
• China Pharmaceutical University / Other Academic InstitutionsminorStrategic or Co-development Partner达仁堂与全国乃至全球多个顶尖研发团队合作，瞄准市场需求创新研发，如在天津与张伯礼院士团队以及现代中医药海河实验室等密切合作。
• AEGLE (安吉尔集团)minorGTM or Marketing Partner天津医药集团联合安吉尔集团共同打造'动销倍增训战营'，聚焦动销能力突破、业绩增量提升，集结两大集团营销核心力量，强化营销体系与终端队伍建设。
• HBG Big Penetration Brand Growth Research Institute (HBG大渗透品牌增长研究院)minorImplementation/ SI/ Consulting Partner动销倍增训战营特邀HBG大渗透品牌增长研究院创始人、院长麦青老师亲临授课，以'用户洞察、产品策略、动销提效、组织保障'为赋能主线，分享动销倍增干货。

Scale indicators35 records

Recent moves6 records

Expansion highlights7 records

Broad incumbents

• Shanghai Pharmaceuticals Holding: One of China's largest state-owned pharmaceutical conglomerates, controlling listed entity Shanghai Pharmaceuticals Holding (601607.SH/2607.HK). Operates across pharmaceutical manufacturing, distribution, and retail. Both groups are SOE pharma conglomerates with mixed TCM and chemical drug portfolios, state-owned governance, and listed subsidiaries.
• China Resources Pharmaceutical Group: Subsidiary of China Resources (Holdings), a central SOE operating across pharmaceutical manufacturing, distribution, and retail. Operates China Resources Sanjiu (TCM), China Resources Double-Crane (chemical drugs), and CR Pharmaceutical Commercial. Comparable as another major SOE pharmaceutical conglomerate with mixed TCM/chemical drug portfolio.
• Guangzhou Pharmaceutical Holdings (GPHL): SOE pharmaceutical conglomerate (parent of listed entities Guangzhou Baiyunshan 600332.SH and Hutchison China MediTech), operating across TCM (陈李济, 敬修堂, 王老吉), chemical drugs, and consumer health. Comparable as another major Chinese pharma conglomerate with similar heritage brand matrix and mixed TCM/chemical drug/consumer health portfolio.
• Sinopharm Group: China's largest pharmaceutical distributor and SOE (H-share 1099.HK), with subsidiaries in pharmaceutical manufacturing and retail pharmacy chains. Comparable as a SOE pharma conglomerate where the distribution arm (Sinopharm Holding) parallels Tianjin Pharma's 津药太平 commercial distribution platform.

Emerging players

• China Grand Pharmaceutical and Healthcare Holdings: Hong Kong-listed pharmaceutical group (512.HK) with branded pharmaceutical manufacturing and emerging cardiovascular/respiratory portfolio. Comparable in Chinese cardiovascular and respiratory drug segments and in international regulatory positioning (FDA/EU), though more focused on Western-style branded pharma than TCM.

Direct peers

• Pien Tze Huang (Zhangzhou Pien Tze Huang): Listed Chinese herbal medicine company (600436.SH) famous for 漳州片仔癀, a state-secret TCM formula. Comparable as another TCM company with state-secret protected flagship products, similar pricing power, premium brand positioning, and similar focus on south-China market expansion and modernized TCM R&D.
• China Traditional Chinese Medicine Holdings (Sinopharm TCM): Hong Kong-listed TCM conglomerate (570.HK) controlled by Sinopharm Group, focused exclusively on Chinese herbal medicine manufacturing and distribution. Direct TCM peer with similar product portfolio (天江药业, 同济堂, etc.) and channel structure. Most comparable pure-play TCM competitor at scale.
• Yunnan Baiyao Group: One of China's most recognized TCM brands (Yunnan Baiyao), publicly listed (000538.SZ). Competes directly with 达仁堂 in branded TCM cardiovascular/oral care segments and has similarly invested in modernization and consumer health expansion. Comparable heritage brand with strong franchise and ongoing innovation pipeline.
• Tongrentang Group: China's most iconic TCM heritage brand (founded 1669), publicly listed subsidiary (600085.SH). Operates Beijing Tongrentang Group with branded TCM products, retail pharmacy chains, and overseas expansion. Direct peer as another multi-century TCM heritage brand with similar cardiovascular and tonifying product franchises and international brand-store ambitions.

Regional players

• Jointown Pharmaceutical Group: Major Chinese pharmaceutical distribution group (600998.SH), now a strategic partner of Tianjin Pharma (Jan 2025 cooperation agreement). Comparable as one of China's top pharma distributors with national coverage, overlapping in commercial distribution segment, and increasingly in branded TCM through partnership with Tianjin Pharma.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights8 records

Customer concentration

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tianjin Pharmaceutical Group International Holdings